Skip to main content

AbCellera Biologics Inc.

ABCL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001703057

In the last 90 days, AbCellera Biologics Inc. insiders filed 4 open-market purchases and 0 sales; 150 institutions reported holding it in 13F filings for Q2 2026, worth $908.8M in total; no superinvestor holds it.

Superinvestors holding ABCL, Q2 2026

See all superinvestors

No superinvestor reported holding ABCL in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of ABCL each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q1 2024

    0 superinvestors holding at quarter end

    Sold out
    Duquesne Family Office
  2. Q3 2023

    1 superinvestor holding at quarter end

    Sold out
    Maverick Capital
  3. Q2 2023

    2 superinvestors holding at quarter end

    Reduced
    Maverick Capital (−20.8%)
  4. Q1 2023

    2 superinvestors holding at quarter end

    Added
    Maverick Capital (+119.6%)
  5. Q4 2022

    2 superinvestors holding at quarter end

    Added
    Maverick Capital (+23.1%)
  6. Q3 2022

    2 superinvestors holding at quarter end

    New
    Maverick Capital
  7. Q3 2021

    1 superinvestor holding at quarter end

    New
    Duquesne Family Office
  8. Q2 2021

    0 superinvestors holding at quarter end

    Sold out
    Viking Global Investors, Duquesne Family Office